Wedbush Reaffirms Outperform Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)

Wedbush reissued their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research report report published on Wednesday morning, RTT News reports. The brokerage currently has a $33.00 target price on the stock. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q3 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.40) EPS.

A number of other analysts have also recently weighed in on the company. Piper Sandler reaffirmed an overweight rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Needham & Company LLC increased their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a buy rating in a research report on Wednesday. HC Wainwright reissued a buy rating and issued a $50.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday. Finally, Oppenheimer reissued a market perform rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of Moderate Buy and a consensus target price of $39.33.

Day One Biopharmaceuticals Stock Up 12.9 %

Shares of NASDAQ DAWN opened at $14.92 on Wednesday. The stock has a market cap of $1.30 billion, a PE ratio of -6.27 and a beta of -1.48. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $17.85. The business has a 50-day moving average price of $15.22 and a 200 day moving average price of $13.81.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Sell-side analysts anticipate that Day One Biopharmaceuticals will post -2.67 earnings per share for the current year.

Insider Activity

In related news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, General Counsel Adam Dubow sold 3,242 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the completion of the transaction, the general counsel now directly owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The disclosure for this sale can be found here. Insiders sold 55,781 shares of company stock valued at $883,160 in the last three months. 8.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock worth $56,807,000 after buying an additional 346,090 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Day One Biopharmaceuticals by 38.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock worth $5,486,000 after buying an additional 125,050 shares in the last quarter. Bank of New York Mellon Corp increased its position in Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after buying an additional 40,387 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Day One Biopharmaceuticals by 41.8% during the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after buying an additional 336,910 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after buying an additional 9,219 shares in the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.